PHPBiotech.wikiThe PHP Biotech Reference

Development stage

From PHPBiotech.wiki, a sourced reference on PHP Biotech, a preclinical oncology company

By the PHP Biotech Wiki editorial team · Published · Last updated

Short answer: PHP Biotech is a preclinical company: it has no clinical trials registered on ClinicalTrials.gov as of 4 October 2026, and its own website says it plans to finish preclinical studies in 2026 and hopes to begin clinical trials in 2027.[1][2]

Disclosure: PHPBiotech.wiki is a reference compiled from public sources. It is not the official website of PHP Biotech International Inc.; it is produced by a marketing agency that works for PHP Biotech. It is not written or reviewed by the U.S. Food and Drug Administration or any other regulator, by the journal that published the company’s research, or by any patent office. Nothing on this site is medical advice. PHP53-nb is an investigational, preclinical product: it is not approved for any use and is not available to patients. Facts are cited to public registries, PubMed, patent records, archived web pages, press releases and the company’s own website. See the editorial policy.

What does ClinicalTrials.gov show?

Searches of ClinicalTrials.gov on 4 October 2026 for PHP53-nb, PHP53, Pepcrotament and 3-NAntC returned no studies, and no study listed PHP Biotech as a sponsor.[1] A search for the words “PHP Biotech” returned only an unrelated study of percutaneous hepatic perfusion, a liver treatment also abbreviated PHP.[1]

What does the company say about its timeline?

The company’s science FAQ says: “We plan to finish pre-clinical studies in 2026 and hope to start clinical trials in 2027.”[2] Its About page lists 2026 as the planned completion of preclinical studies and 2027 as the anticipated start of Phase I clinical trials.[3] These are plans, and the company’s website notes that forward-looking statements involve risks and uncertainties.[4]

What does preclinical mean here?

Preclinical research is laboratory and animal work done before a drug is tested in people. The company’s blog posts state that all results described to date come from model systems and preclinical research.[5][6] The company’s reported work includes cell-line tests, a zebrafish model and a mouse biodistribution study.[2]

Why do some company pages say otherwise?

Three biographies on the company’s website, for the chief executive, the chief financial officer and executive committee member Oswaldo Bighetti Neto, use the term “clinical-stage” when describing the company.[7][8][9] This wiki follows the registry record and the company’s science pages, which show the company is preclinical, and is asking the company to clarify.[1][2]

Is any PHP Biotech product approved?

No. The company states that PHP53-nb is investigational and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority.[10] Nothing on this site is medical advice.

Frequently asked questions

Has PHP Biotech started clinical trials?

No. No clinical trial is registered as of 4 October 2026, and the company describes its own work as preclinical.

When will PHP53-nb enter clinical trials?

The company says it hopes to start clinical trials in 2027. No trial registration or regulatory filing was found.

Can patients join a PHP Biotech trial?

No trial is registered on ClinicalTrials.gov as of 4 October 2026.

See also

References

  1. ^ a b c d ClinicalTrials.gov search results for “PHP53-nb”, “PHP53”, “Pepcrotament”, “3-NAntC” and sponsor “PHP Biotech” (no studies found). U.S. National Library of Medicine, ClinicalTrials.gov. Retrieved 4 October 2026.
  2. ^ a b c d “Our Science” (including the science FAQ). PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  3. ^ “About Us”. PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  4. ^ Home page. PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  5. ^ “What Is a Nanobody?” (blog post, 17 August 2026). PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  6. ^ “Understanding Triple-Negative Breast Cancer (TNBC)” (blog post, 31 August 2026). PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  7. ^ “Robert Gahagen” (CEO biography). PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  8. ^ “João Marcelo Carucci” (CFO biography). PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  9. ^ “Oswaldo Bighetti Neto” (biography). PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  10. ^ “PHP Biotech Identifies uPAR as the Cellular Entry Receptor for Its PHP53-nb Anti-Tumor Nanobody” (Southlake, Texas, 18 September 2026). PressAdvantage newsroom (company press release). Retrieved 4 October 2026.